Immunology & Autoimmune Deal Benchmarks
Over $13B in verified immunology deal value spanning rheumatoid arthritis, lupus, IBD, psoriasis, and other autoimmune conditions. Benchmark licensing terms, M&A premiums, and royalty structures. Benchmarks derived from 420 verified transactions.
420
Total Deals
$448M
Avg Upfront
7
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
215
license
80
acquisition
84
collaboration
30
option
6
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Theravance Biopharma → Zymeworks Inc. YUPELRI (revefenacin) and ampreloxetine | acquisition | $929M | $929M | Sep 2026 |
Sino Biopharmaceutical → AstraZeneca TQC3721 | license | $200M | $2.1B | Sep 2026 |
Haisco-USA Pharmaceuticals → Sentivera Preclinical type 2 inflammatory-disease asset | license | $76M | $1.5B | Aug 2026 |
Sail Biomedicines, Inc. → Johnson & Johnson | option | $785M | $3.5B | Jul 2026 |
Kaigene, Inc. → Taisho Pharmaceutical Co., Ltd. KG006 | license | $5M | $378M | Jul 2026 |
AbCellera Biologics Inc. → Vertex Pharmaceuticals Incorporated T-cell engager / multispecific antibody platform | collaboration | $28M | — | Jul 2026 |
Forte Biosciences → argenx FB102 | acquisition | $2.2B | $2.2B | Jul 2026 |
Sino Bio → AstraZeneca TQC3721 | license | $200M | $2.1B | Jul 2026 |
Junshi Biosciences → Fosun Wanbang roconkibart | license | $32M | $186M | Jul 2026 |
Shanghai Junshi Biosciences → Fosun Wanbang (Jiangsu) Pharmaceutical Group Roconkibart (JS005) | license | $30M | $185M | Jun 2026 |
Benchmark Your Immunology & Autoimmune Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 420 verified immunology & autoimmune transactions.
Immunology & Autoimmune Deal Benchmarking FAQ
What drives immunology deal valuations in 2026?
Immunology deals are increasingly driven by next-generation biologics (IL-17, IL-23, TL1A) and oral small molecules (JAK inhibitors, TYK2). Assets demonstrating superiority over anti-TNF standards of care command premium valuations. The shift toward precision immunology — matching patients to mechanisms — is also driving higher deal values for targeted approaches.
How do IBD deal terms differ from other autoimmune indications?
IBD deals (Crohn's disease and ulcerative colitis) typically feature larger total deal values than other autoimmune indications, reflecting the large patient population and high unmet need. Upfronts for clinical-stage IBD assets range $50M-$200M, with royalties of 12-20% on net sales.
What immunology modalities are attracting the most licensing activity?
Bispecific antibodies targeting dual immune pathways, oral peptides, and cell therapies (including CAR-T for lupus) are generating the most immunology deal activity in 2026. TL1A-targeting antibodies specifically saw a surge in deal-making following positive Phase 2 data across multiple IBD programs.